TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00580905
Drug: Adenosine
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The local effects of adenosine or sodium nitroprusside will be studied in response to microinjection (intradermally) of both drugs. Two microdialysis catheters (CMA 100) will be inserted intradermally in the volar aspect of the forearm after numbing the area with local cold (ice applied in the study area). After 30 minutes,one catheter will be infused with sodium nitroprusside (2microliters/min of a 28 mM solution) and the other with adenosine (2mcl/min of a 100 microM solution) will then be started and continued for 60 minutes. Skin blood flow will be monitored throughout the study with the used of a skin laser Doppler fluxometer mounted adjacent to the area of the microdialysis probe.~A 2 mm skin biopsy punch will be performed 60 minutes after the end of the infusion.
Study: NCT00529841
Drug: Hydrocortisone sodium acetate
Normalized name: Hydrocortisone Sodium Phosphate
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous administration of medication via insulin pump
Study: NCT02158039
Drug: Ethanol
Normalized name: Ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EUS-guided lavage of a pancreatic cystic neoplasm with ethanol solution. Ethanol was diluted to 80% using normal saline.
Study: NCT01744730
Drug: Clindamycin
Normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Schedule includes 30-40 mg/kg/day dosed every 6 or every 8 hours with a maximum daily dose of 2.7 grams/day. Dosing greater than 2.7g/day will be allowed for children receiving clindamycin as part of clinical care.
Study: NCT01527916
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Comparator
Study: NCT01527916
Drug: ABT-126
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: low dose, middle dose, high dose
Study: NCT02534610
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg etoricoxib PO administered 1 h preoperative for group A; group B received 120 mg etoricoxib PO at the end of the surgery.
Study: NCT02534610
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A received 1 sham pill PO at the end of the surgery; group B received 1 sham pill PO 1 h preoperative and group C received sham pill PO 1 h preoperative and 1 sham pill PO at the end of the surgery.
Study: NCT00732121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00233025
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00612313
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will take 10 to 40 mg per day of fluoxetine for 30 weeks.
Study: NCT02556710
Drug: 4 mL injection of Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL Injection of Placebo
Study: NCT01709318
Drug: Estradiol (E2)
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily release of 300 μg
Study: NCT04585334
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tricortin 1000 placebo (2 mL ampoules) will be administered intramuscular on the gluteus, once daily (24 hours apart), for 15 days starting from the evening of Day 0 (visit 2) plus Diclofenac sodium medicated plaster placebo will be applied twice daily (12 hours apart) for 15 days starting from the evening of Day 0 (visit 2), i.e. 30 applications.
Study: NCT01903694
Drug: Sorafenib + Pravastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02229097
Drug: Normal bolus
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the normal bolus period, the bolus will be adjusted to the carbohydrate content of each meal and injected immediately. The basal rate will remain at a normal level during the 3 hours postprandial period
Study: NCT01323569
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 placebo sprays and 4 placebo capsules
Study: NCT01728155
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05905185
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg of Placebo
Study: NCT01010581
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT01010581
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: oral administration
Study: NCT01010581
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration
Study: NCT00809289
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily administration of placebo for 9 days. Placebo will be administered double blind
Study: NCT03226067
Drug: GKT137831
Approvals — FDA: no, EMA: no, PMDA: no
Description: GKT137831 100mg capsules. To be taken as part of two dose arms which are 400mg twice daily or 400mg once daily.
Study: NCT03226067
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching capsules.
Study: NCT00111644
Drug: beta-lactam
Normalized name: Beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750mg iv q 23h for 3-14 days
Study: NCT00111644
Drug: beta-lactam
Normalized name: Beta-lactam
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1500mg iv q 12h for 3-14 days
Study: NCT01662869
Drug: 5-Fluoruracil
Normalized name: 1-(β-D-5-desoxyribofuranoxyl)-5-fluoruracil
DrugBank: Doxifluridine (DB12947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive 5-fluorouracil 400 milligrams per square meter (mg/m\^2) IV bolus and then 2400 mg/m\^2 as a continuous IV infusion over 46-48 hours on Day 1 of every cycle until disease progression or at the maximum of 12 cycles, whichever occurs first.
Study: NCT01662869
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive onartuzumab matching placebo on Day 1 of every cycle (each cycle = 14 days) until disease progression, unacceptable toxicity, or participant or physician decision to discontinue treatment.
Study: NCT01914432
Drug: YH16410
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01914432
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01914432
Drug: YH16410 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01914432
Drug: Rosuvastatin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00907894
Drug: LDT600 (Telbivudine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDT600 (Telbivudine)
Study: NCT00843791
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment with placebo for 3 months
Study: NCT01324024
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: In a counterbalanced fashion, participants would receive placebo tablets for 4 weeks followed by a 2 week washout, then will receive titrated doses of LDX 20 to 60 mg/d for 4 weeks.
Study: NCT01531959
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be randomized to blinded placebo control
Study: NCT02057757
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants 1 to 3 years old: 5 mL placebo oral suspension every 12 hours for 5 days.~Participants 4 to 11 years old: 10 mL placebo oral suspension every 12 hours for 5 days.~Participants 12 years and older: two placebo tablets orally twice daily for 5 days.
Study: NCT02442921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily placebo
Study: NCT00650533
Drug: Amaryl® Tablets 1 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1mg, single dose fed
Study: NCT00621439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive placebo.
Study: NCT00600964
Drug: GX15-070MS
Approvals — FDA: no, EMA: no, PMDA: no
Description: A 60-minute or 3-hour IV infusion every 2-3 weeks.
Study: NCT00600964
Drug: GX15-070MS
Approvals — FDA: no, EMA: no, PMDA: no
Description: GX15-070MS at various doses and schedules
Study: NCT03395535
Drug: Primary Medical Treatment Pathway
Normalized name: zinc pyrithione Medicated Shampoo [Head & Shoulders Damage Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary Medical Treatment Pathway (multiple medications, as required). If IOP not at target additional treatment with all standard medications may be used and ultimately surgery (trabeculectomy ).~All available medical treatments (eye-drops) are permitted according to a pre-specified intervention protocol described in detail in the publicly available trial protocol. This begins with prostaglandin analogues, then beta-blockers followed by alpha agonists or carbonic anhydrase inhibitors. The full range of available doses, treatments and drugs is beyond this short summary.
Study: NCT02461589
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneously ( s.c., under the skin) once daily.
Study: NCT01646034
Drug: carboplatin, thiotepa, and cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: tandem intermediate-dose alkylating therapy: carboplatin 800 mg/m2, thiotepa 240 mg/m2, and cyclophosphamide 3000 mg/m2) with PBPC-reinfusion.
Study: NCT02233231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: similar tabl
Study: NCT03036514
Drug: Patient-controlled intravenous analgesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usage of classically used patient-controlled intravenous mophine-based postoperative analgesia after laminectomy or spinal fusion.
Study: NCT01336465
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeating subcutaneous injection
Study: NCT01048138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5mg IV(in the vein)every 6 hours for 10 days
Study: NCT03880578
Drug: Levothyroxine Sodium
Normalized name: Levothyroxine Sodium
DrugBank: Levothyroxine (DB00451)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: thyroid hormone replacement
Study: NCT02422381
Drug: MK-3475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational drug.
Study: NCT03957174
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose as control condition
Study: NCT01025700
Drug: Cesemat
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg capsule per day for 21 days
Study: NCT02928692
Drug: Minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02928692
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01851005
Drug: Propofol and Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control effect site concentration for maintain BIS 40\~45 and changes of vital signs within 20%.
Study: NCT01851005
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use as placebo
Study: NCT00322062
Drug: macrogol3350 NA sulphate NACL KCL ascorbic acid NA ascorbate
Normalized name: ascorbic acid / polyethylene glycol 3350 / potassium chloride / sodium ascorbate / sodium chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2L gut lavage solution
Study: NCT00574860
Drug: EN3285
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse
Study: NCT00574860
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral rinse
Study: NCT02640729
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, matching tablets
Study: NCT03006406
Drug: Long term GnRH-a (3.75mg)
Normalized name: LONG PEPPER
Approvals — FDA: no, EMA: no, PMDA: no
Description: patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Study: NCT01696032
Drug: Treatment of Choice (topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigator chose to treat with either topotecan, pegylated liposomal doxorubicin, paclitaxel, or gemcitabine
Study: NCT04561362
Drug: BT8009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bicyclic Toxin Conjugate (BTC) administered either weekly (i.e., on Days 1, 8, 15, and 22) or biweekly (Days 1 and 15) on a 28-day cycle or on Days 1 and 8 of a 21-day cycle for participants in A-1. Participants in Cohorts A-2 and B-7 will receive BT8009 weekly on 21-day cycle. Participants in Parts B-1-B-6 will receive BT8009 weekly either on a 21-day or 28-day cycle. Participants in Parts B-8 and B-9 will receive BT8009 on Days 1 and 8 of a 21-day cycle. Participants in Cohort C will receive a 60-minute IV infusion of BT8009 once weekly (i.e., on Days 1, 8, 15, and 22) on a 28-day cycle. Participants in Part D will receive BT8009 once weekly on a 28-day cycle.
Study: NCT01233297
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10 mg/kg peroral for 3 consecutive days
Study: NCT01975389
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcome events, approximately 3 to 4 years after the entry of first subject into the study.
Study: NCT01312961
Drug: Placebo (for Dupilumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection, one subcutaneous injection.
Study: NCT03435094
Drug: Binosto 70Mg Effervescent Tablet
Normalized name: Binosto 70mg Effervescent Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Assess the effect of alendronate 70mg effervescent tablet on bone turnover markers and patient reported outcomes.
Study: NCT00999349
Drug: Silymarin (LEGALON)
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study group: Silymarin Capsule, 140 mg, 3 times a day + desferrioxamine injection 50 mg/kg, Placebo group:Placebo capsules Similar to Silymarin +desferrioxamine injection 50 mg/kg
Study: NCT00999349
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00002495
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 on days 1 and 15
Study: NCT01164046
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: weight adjusted dose of low molecular weight heparin, any type allowed if approved, 65-75% of full therapeutic dose
Study: NCT01164046
Drug: vitamin K antagonists
Normalized name: Vitamin K antagonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Target INR between 2-3. Any type allowed, if approved for use in that country.
Study: NCT02570321
Drug: Anti Fungal Drug
Normalized name: miconazole nitrate Topical Cream [Anti-Fungal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Amphotericin B vs Topical Natamycin
Study: NCT01632579
Drug: LY3023703
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01632579
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT01632579
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered orally
Study: NCT03481946
Drug: BAY1093884
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg/kg given intravenously
Study: NCT03481946
Drug: BAY1093884
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg given intravenously
Study: NCT03156231
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3200m
Study: NCT03966235
Drug: Melatonin 3 mg
Normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin was taken daily for 6 months.
Study: NCT03966235
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet was taken daily for 6 months.
Study: NCT02120924
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form: Topical gel Dosage: Apply gel to the affected areas of the face twice daily for 12 weeks. The amount needed depends upon the size of the lesion site. Assure that enough is applied to adequately cover each lesion. Normally 0.5 g of gel is used on each 5 cm x 5 cm lesion site.
Study: NCT03772405
Drug: Nascum Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: nasal application of nascum plus
Study: NCT03857438
Drug: Ongoing treatment for bipolar mania
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prescribed by the following doctor during hospitalization and after discharge
Study: NCT01688336
Drug: FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFIRINOX will be given intravenously on Days 1, 15, and 28 of each 28 day cycle. Drugs are given in combination in this order:~* Oxaliplatin (85 mg/m2)~* Leucovorin (400mg/ m2)~* Irinotecan (180 mg/m2)~* 5FU (400mg/m2)bolus then 2400 mg/m2 over 46 hours
Study: NCT03208972
Drug: hp-FSH
Normalized name: HP 502
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00268528
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT00268528
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01690403
Drug: EFZ EMT TDF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Study: NCT01513317
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as a 1-hour intravenous infusion every 4 weeks
Study: NCT01513317
Drug: Best supportive care (BSC)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Best supportive care according to local standards and guidelines
Study: NCT02338843
Drug: LJPC-501
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment arm
Study: NCT02338843
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PBO
Study: NCT01825551
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01032694
Drug: Azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin SR, 2.0 g PO x 1 dose for treatment period
Study: NCT01032694
Drug: Amoxiclav
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxiclav 1000 x twice daily, 10 days duration
Study: NCT01027910
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered intravenously on Day 4 of each 3 week cycle
Study: NCT02805842
Drug: Advagraf QD
Normalized name: Astagraf
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of Advagraf QD
Study: NCT03063229
Drug: Hepatic Mitochondrial Oxidation breath test
Normalized name: hepatitis nosodes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will be given a calculated amount of the stable isotope C-Octanoate, which will be delivered in a water solution. They will then be asked to breath down a small tube into a clear plastic collection bag 10 times over 2 hours.
Study: NCT02855502
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02855502
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01657201
Drug: SYP-1018 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: SYP-1018 200mg, Intravenous administration
Study: NCT02497326
Drug: Topical Heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin solution (5000 IU/ml) will be sprinkled aseptically on burn surface twice a day for the first 2 days, by #27 needle connected via drip set to the drip containing heparin aqueous saline. The dose will be reduced to 75% of day 1 on day 3 and 4 and to 50% on day 5. Administration of heparin saline solution will be in 3 cycles with 5-10 minutes interval
Study: NCT01040871
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Study: NCT01040871
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous on Day 1 of a 21 day (3 week) cycle for 6 cycles
Study: NCT01256775
Drug: NCX4016 placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: NCX4016 placebo b.i.d. for 6 months
Study: NCT01984723
Drug: Experimental: EVP-6124
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01465802
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline or Doxycycline placebo BID for 4 weeks
Study: NCT03037151
Drug: Grazaoprevir/Elbasavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment naive
Study: NCT03037151
Drug: Grazaoprevir/Elbasavir/RBV
Approvals — FDA: no, EMA: no, PMDA: no
Description: treatment experienced
Study: NCT02773797
Drug: IN-DEX 1.5 mcg/kg, intranasal saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02773797
Drug: Placebo - Saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02252081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo pill(s) orally per day for 16 weeks
Study: NCT02595684
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcined magnesia capsules: one per day, at night, during 28 days.
Study: NCT03503968
Drug: MDG1011
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRAME-T-Cell Receptor Gene Modified Autologous T Cells
Study: NCT03771729
Drug: LCZ 696
Approvals — FDA: no, EMA: no, PMDA: no
Description: LCZ696 200mg twice daily
Study: NCT02044081
Drug: C16G2 Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active rinses are 1.6 mg/mL C16G2.
Study: NCT02044081
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is the vehicle without C16G2
Study: NCT02044081
Drug: C16G2 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active C16G2 Gel is 3.2 mg/mL
Study: NCT02639377
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution chemical manufactured to mimic 0.12% chlorhexidine mouthwash
Study: NCT01903278
Drug: PEG-IFN-SA /RBV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01903278
Drug: Pegasys /RBV
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02823925
Drug: Pamidronate or Zoledronate
Approvals — FDA: no, EMA: no, PMDA: no